Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CHOP spins off Spark Therapeutics, launches with $50mm Series A round

Executive Summary

Children’s Hospital of Philadelphia (CHOP)’s Center for Cellular & Molecular Therapeutics (CCMT) spun out Spark Therapeutics LLC, which will pursue gene therapies advanced by CHOP in ophthalmic, neurodegenerative, and blood diseases. CHOP, which retains majority ownership of Spark, committed $50mm in Series A financing to the start-up over the next several years on an as-needed basis. CHOP invested an initial $10mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies